Open AccessCombination of a synthetic retinoid and a DNA demethylating agent induced differentiation of neuroblastoma through retinoic acid signal reprogramming
Author(s) -
Naoko Hattori,
Kiyoshi Asada,
Nozomu Miyajima,
Akiko Mori,
Yoko Nakanishi,
Kana Kimura,
Mika Wakabayashi,
Hideyuki Takeshima,
Chika Nitani,
Junichi Hara,
Toshikazu Ushijima
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01571-y
Subject(s) - retinoic acid , reprogramming , retinoid , neuroblastoma , demethylating agent , tretinoin , cellular differentiation , biology , cancer research , microbiology and biotechnology , genetics , cell culture , dna methylation , cell , gene , gene expression
The CpG island methylator phenotype of neuroblastoma (NBL) is strongly associated with poor prognosis and can be targeted by 5-aza-2'-deoxycytidine (5-aza-dC). Differentiation therapy is a standard maintenance therapy for high-risk NBLs. However, the in vivo effect of tamibarotene, a synthetic retinoic acid, and the efficacy of its combination with 5-aza-dC have not been studied. Here, we conducted a preclinical study to assess the in vivo tamibarotene effect and the combination.